14628-34-3

Usage

Uses

Used in Pharmaceutical Industry:
5-Chloro-2-methylpyridazin-3(2H)-one is used as a potential antitumor and antifungal agent for its ability to inhibit the growth of cancer cells and its potential as a lead compound for drug development.
Used in Medicinal Chemistry:
5-Chloro-2-methylpyridazin-3(2H)-one is used as an inhibitor of certain enzymes, contributing to its potential applications in the field of medicinal chemistry and drug discovery.

Upstream product

• 14628-58-1 5-methoxy-2-methylpyridazin-3(2H)-one 
• 933-76-6 4,5-dichloro-2-methyl-3(2H)-pyridazinone 
• 14628-57-0 4-chloro-5-methoxy-2-methyl-2H-pyridazin-3-one 
• 74-88-4 methyl iodide 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 40636-99-5 4-chloro-5-hydroxy-<5H>-furan-2-one 
• 60-34-4 methylhydrazine 

Downstream Products

• 98700-58-4 5-<(3-tert-Butyl-2-phenyl-1,3-oxazolidin-5-yl)methoxy>-2-methylpyridazin-3(2H)-one 
• 87633-93-0 N-benzyl-N,N-(2,2'-dimethyl-3,3'-dioxo-2,3,2',3'-tetrahydro-4,5')dipyridazinylamine 
• 87633-91-8 2,6-dimethyl-9-benzyl-9H-dipyridazino<4,5-b:4',5'-d>pyrrole-1,5(2H,6H)-dione 
• 1262422-95-6 5-[4-(3-chloro-phenylethynyl)-2-methyl-imidazol-1-yl]-2-methyl-2H-pyridazin-3-one 
• 1621525-40-3 5-(3-iodo-1H-pyrazol-1-yl)-2-methylpyridazin-3(2H)-one 
• 1458655-56-5 5-(4-amino-3,5-dimethylphenyl)-2-methylpyridazin-3(2H)-one 
• 40995-48-0 2.5-Dimethyl-4-oxo-4.5-dihydropyrazolo<3.4-d>pyridazin 
• 40995-50-4 1,5-dihydro-1,5-dimethyl-4H-pyrazolo<3,4-d>pyridazin-4-one 

Relevant academic research and scientific papers

Synthesis method of 2-methyl-5 chloro pyridazinone

The invention discloses a synthesis method of 2-methyl-5 chloro pyridazinone, and the method includes the following steps: a, refluxing 4-chloro-5-hydroxy-5 H-furan-2-one and methylhydrazine in glacial acetic acid for reaction; b, adding water to a reaction solution after the reaction, using NaHCO3 or NaCO3 to adjust the pH of the solution to alkaline, using the solution for extraction, drying an obtained organic phase with anhydrous sodium sulfate, and concentrating the organic phase to obtain a white solid; and c, purifying the obtained white solid by column chromatography with a mixed solvent of ethyl acetate and petroleum ether. By the way, the synthesis method has the advantages of simple operation, low cost and easy industrialization, and meets the technological requirements of green chemistry.

5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE

5-Azaindazole compounds of Formula (I), including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

FACTOR IXA INHIBITORS

The present invention provides a compound of Formula (I) (structurally represented) wherein R1 is H or C1-6 alkyl, R2 is H or C1-6 alkyl or CH20H, R3 is H or C1-6 alkyl, and R4 is H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, then R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl or-CH20H, and when R2, R3, and R4 are H, then R1 is C 1-6 alkyl; A is 1 ) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and 0, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R5 and unsubstituted or substituted with R6 and unsubstituted or substituted with NH2, or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R5, unsubstituted or substituted with R6, and unsubstituted or substituted with -CH2NH2; and B is 1) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or 0, which is unsubstituted or substituted on a carbon or nitrogen atom with R7, unsubstituted or substituted on a carbon or nitrogen atom with R8, and unsubstituted or substituted on a carbon or nitrogen atom with R9, or 2) an 8- or 9-membered fused bicyclic heterocycle having 1, 2 or 3 nitrogen atoms which is unsubstituted or substituted on a carbon or nitrogen atom with R7, and unsubstituted or substituted on a carbon or nitrogen atom with R8; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS

The present invention relates to compounds of general formula I, (I), wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS

The present invention relates to imidazole derivatives of the general formula (I) wherein R1 signifies halogen, lower alkyl or lower alkoxy; R2 signifies lower alkyl, lower hydro xyalkyl or lower alkoxyalkyl; R3 signifies hydrogen, lower alkyl, lower hydroxyalkyl or alkoxyalkyl; Q signifies either -N= or -CH=; R4 is a group of formula IIa or lIb (formula IIa and IIb) wherein X, Y and Z independently are -CH= or -N=, and whereby only one of X or Y can be a nitrogen atom; R5 and R6 independently are hydrogen, lower alkyl, lower hydroxyalkyl, lower alkoxyalkyl, -(CH2)m-(CO)O-lower alkyl, -(CH2)m-S(O)2-lower alkyl, -(CH2)m-C(O)-NR'R" and where m = 0-3 and R' and R'' are independently hydrogen or lower alkyl; as well as to pharmaceutically acceptable salts thereof. It has now surprisingly been found that the compounds of general formula (I) are metabotropic glutamate receptor antagonists. They can be used in the treatment or prevention of mGluR5 receptor mediated disorders.